Porphyria Cutanea Tarda: Evidence‑Based Clinical Guidelines

Clinical Presentation

Adults in their fifth to sixth decade commonly develop skin fragility and blistering lesions on sun‑exposed areas such as the hands and face, characteristic of porphyria cutanea tarda. 1
Bullae, hyperpigmentation, and erosions appear on sun‑exposed skin (hands, face) in affected individuals. 3

The disease manifests only when a partial deficiency of uroporphyrinogen decarboxylase (URO‑D) is combined with additional susceptibility factors (e.g., iron overload, alcohol, infections). 4
Hepatitis C virus infection has a demonstrated pathogenetic role in precipitating porphyria cutanea tarda, particularly in certain geographic regions. 3

Sporadic (type I) PCT – hepatic URO‑D activity is reduced to about 50 % of normal, without a germline mutation; the condition is usually non‑hereditary. 1

Biochemical confirmation (elevated serum and urinary porphyrins) must be obtained before any genetic testing is performed. 1
A 24‑hour urine porphyrin measurement that shows increased uroporphyrins is diagnostic for porphyria cutanea tarda. 3
Serum porphyrin quantification should be performed as part of the diagnostic work‑up. 4
Assessment of URO‑D enzyme activity demonstrates the underlying enzymatic deficiency. 3
Liver function testing and evaluation for underlying liver disease are recommended to identify co‑existing hepatic pathology. 3

Routine surveillance with liver ultrasound and α‑fetoprotein every six months is advised for hepatocellular carcinoma screening in patients with cirrhosis or advanced fibrosis. 5
Mild elevations of liver enzymes are common; approximately 13 % of patients show raised transaminases during active disease. 5